Guidance for anti-VEGF intravitreal injections during the COVID-19 pandemic

Purpose There is an urgent need to address how to best provide ophthalmic care for patients with retinal disease receiving intravitreal injections with anti-vascular endothelial growth factor agents during the ongoing global COVID-19 pandemic. This article provides guidance for ophthalmologists on h...

Full description

Autores:
Tipo de recurso:
Fecha de publicación:
2020
Institución:
Universidad del Rosario
Repositorio:
Repositorio EdocUR - U. Rosario
Idioma:
eng
OAI Identifier:
oai:repository.urosario.edu.co:10336/24776
Acceso en línea:
https://doi.org/10.1007/s00417-020-04703-x
https://repository.urosario.edu.co/handle/10336/24776
Palabra clave:
Retinal disease
Ophthalmology
COVID-19
Coronavirus
Recommendations
Vision Academy
Rights
License
Abierto (Texto Completo)
id EDOCUR2_31c5a92e13a0452f79436a4f25991292
oai_identifier_str oai:repository.urosario.edu.co:10336/24776
network_acronym_str EDOCUR2
network_name_str Repositorio EdocUR - U. Rosario
repository_id_str
dc.title.spa.fl_str_mv Guidance for anti-VEGF intravitreal injections during the COVID-19 pandemic
title Guidance for anti-VEGF intravitreal injections during the COVID-19 pandemic
spellingShingle Guidance for anti-VEGF intravitreal injections during the COVID-19 pandemic
Retinal disease
Ophthalmology
COVID-19
Coronavirus
Recommendations
Vision Academy
title_short Guidance for anti-VEGF intravitreal injections during the COVID-19 pandemic
title_full Guidance for anti-VEGF intravitreal injections during the COVID-19 pandemic
title_fullStr Guidance for anti-VEGF intravitreal injections during the COVID-19 pandemic
title_full_unstemmed Guidance for anti-VEGF intravitreal injections during the COVID-19 pandemic
title_sort Guidance for anti-VEGF intravitreal injections during the COVID-19 pandemic
dc.subject.keyword.spa.fl_str_mv Retinal disease
Ophthalmology
COVID-19
Coronavirus
Recommendations
Vision Academy
topic Retinal disease
Ophthalmology
COVID-19
Coronavirus
Recommendations
Vision Academy
description Purpose There is an urgent need to address how to best provide ophthalmic care for patients with retinal disease receiving intravitreal injections with anti-vascular endothelial growth factor agents during the ongoing global COVID-19 pandemic. This article provides guidance for ophthalmologists on how to deliver the best possible care for patients while minimizing the risk of infection. Methods The Vision Academy's Steering Committee of international retinal disease experts convened to discuss key considerations for managing patients with retinal disease during the COVID-19 pandemic. After reviewing the existing literature on the issue, members put forward recommendations that were systematically refined and voted on to develop this guidance. Results The considerations focus on the implementation of steps to minimize the exposure of patients and healthcare staff to COVID-19. These include the use of personal protective equipment, adherence to scrupulous hygiene and disinfection protocols, pre-screening to identify symptomatic patients, and reducing the number of people in waiting rooms. Other important measures include triaging of patients to identify those at the greatest risk of irreversible vision loss and prioritization of treatment visits over monitoring visits where possible. In order to limit patient exposure, ophthalmologists should refrain from using treatment regimens that require frequent monitoring. Conclusion Management of patients with retinal disease receiving intravitreal injections during the COVID-19 pandemic will require adjustment to regular clinical practice to minimize the risk of exposure of patients and healthcare staff, and to prioritize those with the greatest medical need. The safety of patients and healthcare staff should be of paramount importance in all decision-making.
publishDate 2020
dc.date.accessioned.none.fl_str_mv 2020-06-11T13:21:13Z
dc.date.available.none.fl_str_mv 2020-06-11T13:21:13Z
dc.date.created.spa.fl_str_mv 2020-04-23
dc.type.eng.fl_str_mv article
dc.type.coarversion.fl_str_mv http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.coar.fl_str_mv http://purl.org/coar/resource_type/c_6501
dc.type.spa.spa.fl_str_mv Artículo
dc.identifier.doi.none.fl_str_mv https://doi.org/10.1007/s00417-020-04703-x
dc.identifier.issn.none.fl_str_mv 0721-832X
1435-702X
dc.identifier.uri.none.fl_str_mv https://repository.urosario.edu.co/handle/10336/24776
url https://doi.org/10.1007/s00417-020-04703-x
https://repository.urosario.edu.co/handle/10336/24776
identifier_str_mv 0721-832X
1435-702X
dc.language.iso.none.fl_str_mv eng
language eng
dc.relation.citationEndPage.none.fl_str_mv 8
dc.relation.citationStartPage.none.fl_str_mv 1
dc.relation.citationTitle.none.fl_str_mv Graefe`s Archive for Clinical and Experimental Ophthalmology
dc.relation.ispartof.spa.fl_str_mv Graefe's Archive for Clinical and Experimental Ophthalmology, ISSN: 0721-832X;1435-702X, No. (2020-04-23); pp. 1-8
dc.relation.uri.spa.fl_str_mv https://link.springer.com/content/pdf/10.1007/s00417-020-04703-x.pdf
dc.rights.coar.fl_str_mv http://purl.org/coar/access_right/c_abf2
dc.rights.acceso.spa.fl_str_mv Abierto (Texto Completo)
rights_invalid_str_mv Abierto (Texto Completo)
http://purl.org/coar/access_right/c_abf2
dc.format.mimetype.none.fl_str_mv application/pdf
dc.publisher.spa.fl_str_mv Graefe's Archive for Clinical and Experimental Ophthalmology
institution Universidad del Rosario
dc.source.instname.spa.fl_str_mv instname:Universidad del Rosario
dc.source.reponame.spa.fl_str_mv reponame:Repositorio Institucional EdocUR
bitstream.url.fl_str_mv https://repository.urosario.edu.co/bitstreams/093bcab5-eedd-47fe-a818-fe24e531c27b/download
https://repository.urosario.edu.co/bitstreams/fafec991-9163-4a91-bcce-5765b752a819/download
https://repository.urosario.edu.co/bitstreams/74db41a6-cca4-4267-b1e7-15c71683405c/download
bitstream.checksum.fl_str_mv 14dba7c1b699ff6304de93cf35a229a5
17dcf5c17f9fde4ac9e66d19d6f15f22
008b5ea1f8fa97c14f936ea60691bd5b
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
repository.name.fl_str_mv Repositorio institucional EdocUR
repository.mail.fl_str_mv edocur@urosario.edu.co
_version_ 1818106528249413632
spelling 8b521d7e-5e5e-4b4a-bab5-168bdb189eb0-16f15a7e9-21b9-4a10-bf18-07de8b648e9a-11bc9b933-7d8c-4bde-bba7-e251c6c33e0b-183353ab2-f2d2-400b-a407-3f26b6ed2bb8-1b21c4f8f-b9ab-4a07-a97d-65b60982da34-19a0f36dd-55c1-4175-bbdc-bbd55b4cbaf4-19e2973d5-6b0c-4568-b949-214b690498b7-123f32c73-f71c-415b-b229-a7ea64605d19-19c2f9029-f72d-4a62-8c52-82fafe0b5c10-1c5eb83f7-7c14-4c82-b057-7c9a6950de14-1799c21f0-641d-43c1-9912-c7a55210fdb5-1e27c1a08-d48c-4f4c-8598-a7691846e08a-146cf489a-6cbe-4d89-b5b9-26afc9eca194-160495f22-0781-479b-9969-803d572bdbbf-1e9382a84-7532-4238-a6e9-d0b1e9cc130f-12020-06-11T13:21:13Z2020-06-11T13:21:13Z2020-04-23Purpose There is an urgent need to address how to best provide ophthalmic care for patients with retinal disease receiving intravitreal injections with anti-vascular endothelial growth factor agents during the ongoing global COVID-19 pandemic. This article provides guidance for ophthalmologists on how to deliver the best possible care for patients while minimizing the risk of infection. Methods The Vision Academy's Steering Committee of international retinal disease experts convened to discuss key considerations for managing patients with retinal disease during the COVID-19 pandemic. After reviewing the existing literature on the issue, members put forward recommendations that were systematically refined and voted on to develop this guidance. Results The considerations focus on the implementation of steps to minimize the exposure of patients and healthcare staff to COVID-19. These include the use of personal protective equipment, adherence to scrupulous hygiene and disinfection protocols, pre-screening to identify symptomatic patients, and reducing the number of people in waiting rooms. Other important measures include triaging of patients to identify those at the greatest risk of irreversible vision loss and prioritization of treatment visits over monitoring visits where possible. In order to limit patient exposure, ophthalmologists should refrain from using treatment regimens that require frequent monitoring. Conclusion Management of patients with retinal disease receiving intravitreal injections during the COVID-19 pandemic will require adjustment to regular clinical practice to minimize the risk of exposure of patients and healthcare staff, and to prioritize those with the greatest medical need. The safety of patients and healthcare staff should be of paramount importance in all decision-making.application/pdfhttps://doi.org/10.1007/s00417-020-04703-x0721-832X1435-702Xhttps://repository.urosario.edu.co/handle/10336/24776engGraefe's Archive for Clinical and Experimental Ophthalmology81Graefe`s Archive for Clinical and Experimental OphthalmologyGraefe's Archive for Clinical and Experimental Ophthalmology, ISSN: 0721-832X;1435-702X, No. (2020-04-23); pp. 1-8https://link.springer.com/content/pdf/10.1007/s00417-020-04703-x.pdfAbierto (Texto Completo)http://purl.org/coar/access_right/c_abf2instname:Universidad del Rosarioreponame:Repositorio Institucional EdocURRetinal diseaseOphthalmologyCOVID-19CoronavirusRecommendationsVision AcademyGuidance for anti-VEGF intravitreal injections during the COVID-19 pandemicarticleArtículohttp://purl.org/coar/version/c_970fb48d4fbd8a85http://purl.org/coar/resource_type/c_6501Korobelnik, Jean-FrançoisLoewenstein, AnatEldem, BoraJoussen, Antonia M.Koh, AdrianLambrou, George N.Lanzetta, PaoloLi, XiaoxinLövestam-Adrian, MonicaNavarro, RafaelOkada, Annabelle A.Pearce, IanRodríguez, Francisco J.Wong, David T.Wu, LihtehORIGINALKorobelnik2020_Article_GuidanceForAnti-VEGFIntravitre.pdfapplication/pdf388739https://repository.urosario.edu.co/bitstreams/093bcab5-eedd-47fe-a818-fe24e531c27b/download14dba7c1b699ff6304de93cf35a229a5MD51TEXTKorobelnik2020_Article_GuidanceForAnti-VEGFIntravitre.pdf.txtKorobelnik2020_Article_GuidanceForAnti-VEGFIntravitre.pdf.txtExtracted texttext/plain39045https://repository.urosario.edu.co/bitstreams/fafec991-9163-4a91-bcce-5765b752a819/download17dcf5c17f9fde4ac9e66d19d6f15f22MD52THUMBNAILKorobelnik2020_Article_GuidanceForAnti-VEGFIntravitre.pdf.jpgKorobelnik2020_Article_GuidanceForAnti-VEGFIntravitre.pdf.jpgGenerated Thumbnailimage/jpeg4527https://repository.urosario.edu.co/bitstreams/74db41a6-cca4-4267-b1e7-15c71683405c/download008b5ea1f8fa97c14f936ea60691bd5bMD5310336/24776oai:repository.urosario.edu.co:10336/247762021-06-03 00:50:35.014https://repository.urosario.edu.coRepositorio institucional EdocURedocur@urosario.edu.co